A Breakthrough in Softgel Capsule Technology: Rousselot’s StabiCaps Innovation

Rousselot, a prominent supplier of gelatin and collagen peptides, has recently received a US patent for its revolutionary StabiCaps technology. This innovative gelatin solution aims to address the common issue of crosslinking in softgel capsules, which often leads to the slow or incomplete release of nutrients or pharmaceutical ingredients contained within the capsule.

The occurrence of crosslinking happens when softgels are exposed to specific active compounds or poor storage conditions, resulting in the formation of molecular bonds within the capsule shell that restrict or prevent its dissolution. This can significantly impact the stability and effectiveness of the softgel capsules, ultimately affecting the overall quality of the product.

Pierre-Albert Thomas, the Functional Ingredients Director at Rousselot, has emphasized the significance of StabiCaps for softgel manufacturers, highlighting gelatin as a primary ingredient in softgel production. The recently obtained US patent now allows manufacturers in the US to utilize the advantages of StabiCaps gelatin technology to produce high-quality softgels with improved shelf stability and effectiveness, ultimately benefiting the end consumers.

The importance of this patent extends beyond the US market, as Rousselot has also obtained a patent from the European Patent Office (EPO) for StabiCaps, covering all major European countries. This signifies a major milestone for the company and reaffirms its dedication to advancing softgel technology on a global scale.

Softgel capsules are widely preferred for their ease of swallowing and their ability to mask unpleasant odours and tastes. As a result, the global softgels market is expected to experience significant growth, with a projected compound annual growth rate of 4.3% from 2023 to 2033. This emphasizes the importance of technological advancements, such as StabiCaps, in meeting the growing demand for high-quality softgel products.

StabiCaps forms a part of Rousselot’s extensive range of gelatin solutions for the nutraceutical and pharmaceutical markets. Their portfolio also includes SiMoGel, an innovative technology that enables starch-free gummy production. These cutting-edge solutions highlight Rousselot’s commitment to delivering world-class products that meet the evolving needs of the industry and consumers.

In conclusion, the granting of the US patent for StabiCaps is a significant accomplishment for Rousselot, paving the way for enhanced softgel production in the US market. With the potential to improve the stability and effectiveness of softgel capsules, StabiCaps represents a crucial advancement in the field of gelatin technology, offering tangible benefits for manufacturers and consumers.